"selective primary health care" - Google News

[unable to retrieve full-text content]

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)  Novartis

Comments

Popular posts from this blog

Global Influenzavirus B Infection Drug Market 2019 - AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp Business Pulze - Business Pulze

Healthcare layoff tracker—Walmart cuts 74 virtual health jobs - Fierce healthcare